ClinicalTrials.gg
CompletedNCT07811882PLATINUMUpdated Sep 10, 2026

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)

A Phase 2 interventional study of KAE609 (Cipargamin) and SoC (Coartem) in Uncomplicated Plasmodium Falciparum Malaria, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 7 countries. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2025, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
12 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Malaria, Falciparum by Novartis — 2 open to participants now, 2 under way, none of them phase 3. Malaria, Falciparum · Novartis.

Enrollment
9th of 13
95 · median 265
Started
2025
the only one that year
Phase 2
7 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Malaria, Falciparum by Novartis, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 7 in phase 2, and was the 12th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

2 of the 13 studies in Malaria, Falciparum by Novartis are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Malaria, Falciparum by Novartis, or all of them as a file.
02

Study summary

This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.

Read the detailed description

The Cohort B1 of this Platfom study (NCT05750628) is the open-label, randomized, two-arm combination therapy evaluating a dose of up to two anti-malarial agents as a loose combination vs. standard of care (SoC), Coartem in adult and adolescent participants.

03

Conditions studied

  • Uncomplicated Plasmodium Falciparum Malaria

Browse trials for

Keywords

  • single dose cure malaria
  • uncomplicated malaria
  • Plasmodium falciparum
  • platform study
  • PLATINUM
04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients ≥12 years of age at screening.
  2. Patients must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 1,000 to 150,000 asexual parasite count/μl of blood for P. falciparum.
  3. Patients must weigh between 35 kg and 90 kg at screening.
  4. Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours.

Exclusion criteria

Exclusion Criteria:

  1. Patients with signs and symptoms of severe/complicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening
  2. Moderate to severe anemia, chronic hemoglobinopathy ( level \< 8 g/dL), or known chronic underlying disease such as sickle cell disease at screening
  3. Known liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:

    • /ALT > 3 x the (ULN), regardless of the level of total
    • AST/ALT > 1.5 and ≤ 2 x ULN and total bilirubin is > ULN
    • Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
  4. Any known/suspected or immunodeficient condition, including (HIV) infection at screening.
  5. Pregnant or nursing (lactating) women, women of , defined as all women physiologically capable of becoming pregnant, unless they are using methods of effective , and sexually active patients not willing to practice effective contraception.
  6. History or current diagnosis of abnormalities indicating significant risk of safety for patients participating in the study such as:

    • Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker
    • History of familial long syndrome or known family history of Torsades de Pointe.
    • Resting heart rate (physical exam or 12 lead ECG) \< 50 bpm

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Cohort B1: Cipargamin + INE963

    Cohort B1: Cipargamin + INE963

    Drug: KAE609 (Cipargamin) · Drug: INE963

  • Active comparator
    Cohort B1: SoC (Artemether 80 mg + lumefantrine 480 mg)

    Cohort B1: SoC (Artemether 80 mg + lumefantrine 480 mg)

    Drug: SoC (Coartem)

Interventions

06

What researchers measure

Primary outcomes

  1. Polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR)

    ACPR is defined as the absence of parasitemia on Study Day 29 irrespective of axillary temperature, without previously meeting any of the criteria of Early Treatment Failure (ETF) or Late Clinical Failure (LCF) or Late Parasitological Failure (LPF).

    Time frame: Day 29

Secondary outcomes

  1. Parasite clearance time (PCT)

    To assess the parasite clearance time (PCT) of oral anti malarial agent versus the standard of care (SoC) in participants with uncomplicated P. falciparum malaria

    Time frame: up to Day 7

  2. PCR-uncorrected ACPR

    To assess the 28-day cure rate of an anti malarial agent administered orally as combination therapy versus the SoC in participants with uncomplicated P. falciparum malaria.

    Time frame: Day 29

  3. Area under the concentration-time curve from time zero to the last measurable concentration sampling time (AUClast)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

  4. Maximum observed concentration (Cmax)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

  5. Time to reach maximum observed concentration (Tmax)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

  6. Elimination half-life (T1/2)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

  7. Total body clearance (CL/F)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

  8. Apparent volume of distribution (V/F)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

  9. Area under the concentration-time curve from time zero to infinity (AUCinf)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

  10. Area under the concentration-time curve (AUC0-t)

    To characterize the pharmacokinetics (PK) of the anti-malarial agent administered orally as combination therapy.

    Time frame: Day 8

07

Study locations

13 sites
  • Novartis Investigative Site
    Banfora, Burkina Faso
  • Novartis Investigative Site
    Nanoro, BP 18, Burkina Faso
  • Novartis Investigative Site
    Abidjan, 13BP972, Côte d’Ivoire
  • Novartis Investigative Site
    Azaguié, BP 173, Côte d’Ivoire
  • Novartis Investigative Site
    Lambaréné, BP 242, Gabon
  • Novartis Investigative Site
    Libreville, BP 1437, Gabon
  • Novartis Investigative Site
    Kintampo, 92037, Ghana
  • Novartis Investigative Site
    Navrongo, VWJ6+8WF, Ghana
  • Novartis Investigative Site
    Ahero, 40100, Kenya
  • Novartis Investigative Site
    Kisumu, 40100, Kenya
  • Novartis Investigative Site
    Kigali, BP 4560, Rwanda
  • Novartis Investigative Site
    Kampala, 101, Uganda
  • Novartis Investigative Site
    Tororo, 10102, Uganda
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jun 2026, 8 months.

Of 39 phase 2 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 10, 2026
StartActual
Oct 10, 2025
Primary completionActual
Jun 17, 2026
CompletionActual
Jul 1, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07811882
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Oct 10, 2025
Primary completion
Jun 17, 2026
Completion
Jul 1, 2026
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INE963

Start the discussion